Advertisement

Topics

Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Company Profile

21:01 EDT 24th September 2018 | BioPortfolio


News Articles [2217 Associated News Articles listed on BioPortfolio]

Janssen, Bristol-Myers Squibb Team Up to Develop Therapy

Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thr...

Bristol-Myers Squibb and Gritstone to start Phase l trial for tumours

Bristol-Myers Squibb Company has entered a clinical trial collaboration with Gritstone Oncology to examine the safety and tolerability of GRANITE-001...Read More... The post Bristol-Myers Squibb and G...

Bristol-Myers Squibb And Flatiron Health Expand Collaboration

NewsBristol-Myers Squibb will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its canc...

Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration

NewsBristol-Myers Squibb and Gritstone Oncology have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy in combi...

Bristol-Myers Squibb (BMY) Expected to Announce Quarterly Sales of $5.38 Billion

Brokerages forecast that Bristol-Myers Squibb will post $5.38 billion in sales for the current fiscal quarter, according to Zacks Investment Research . Four analysts have made estimates for Bristol-My...

Bristol-Myers Squibb to Take Part in Barclays Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Global Healthcare Conference on Wednesday, March 14, 2018, in Miami. Murdo Gordon, executive vice presiden...

Bristol-Myers Squibb Foundation’s $25M Commitment to Cancer Moonshot Recognized at AACR Annual Meeting

SOURCE: Bristol-Myers Squibb Company DESCRIPTION:The Bristol-Myers Squibb Foundation’s commitment to address health disparities in cancer outcomes and care was represented at the Biden Cancer Initia...

Bristol-Myers Squibb and Flatiron Health Expand Collaboration to Accelerate Cancer Research and Development Efforts

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade re...

PubMed Articles [2739 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.

Indoleamine 2,3-dioxygenase is a heme-containing enzyme implicated in the down regulation of the anti-tumor immune response, and considered a promising anti-cancer drug target. Several pharmaceutical ...

THE EFFECT OF TOTAL AND PARTIAL NEPHRECTOMY ON THE PHARMACOKINETICS OF INTRAVENOUS PARACETAMOL IN HUMANS.

Paracetamol is one of the most common analgesic and antipyretic drugs. Recently intravenous paracetamol has been widely used to treat moderate postoperative pain. Surgery is the main method of treatme...

A Pilot Experiment in Responding to Individual Patient Requests for Compassionate Use of an Unapproved Drug: The Compassionate Use Advisory Committee (CompAC).

Janssen Research & Development, LLC, part of the Janssen pharmaceutical companies of Johnson & Johnson, and NYU School of Medicine partnered to establish the Compassionate Use Advisory Committee (Comp...

What research is needed to validate new urodynamic methods? ICI-RS2017.

In recent years urodynamic innovations, although well researched, have failed to follow a standardized development pathway specifically in terms of clinical trials undertaken to demonstrate efficacy. ...

Clinical Trials [3599 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Pravastatin 80 mg Tablets Dosed in Healthy Subjects Under Non-Fasting Conditions

This study compared the relative bioavailability (rate and extent of absorption) of Pravastatin Sodium Tablets 80 mg by Teva Pharmaceutical Industries, Ltd. with that of Pravachol® Tablet...

Companies [5709 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

More Information about "Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC" on BioPortfolio

We have published hundreds of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC news stories on BioPortfolio along with dozens of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Clinical Trials and PubMed Articles about Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Companies in our database. You can also find out about relevant Bristol-Myers Squibb Company and Pharmacyclics, Inc. and Janssen Research & Development, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record